Login
Companies $KZIA
$5.60 +$0.00 (0.0%) After hours
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD

kaziatherapeutics.com

What Do They Do?

Develops oncology drug candidates, including a treatment designed for brain cancer and another candidate for cancer indications.

How Do They Make Money?

Receives payments from licensees for rights to use its intellectual property when a license is transferred; agreements may also provide milestone payments if clinical, regulatory or commercial targets are met.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost AUD 20.7M in FY2025.

Net income, FY2025
−49290% of revenue
▲ +23% (Loss) vs FY2024 (−AUD 26.8M, −1160%)

How Are They Changing?

Paxalisib expands beyond brain cancer The older report described paxalisib development in primary and metastatic brain cancers; the latest report also describes a company-sponsored trial in advanced triple-negative breast cancer combining paxalisib with pembrolizumab and chemotherapy.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support